UNSPSC 51171983: Rabeprazole

This classification denotes a proton pump inhibitor with the molecular formula C18H21N3O3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 32828355LL, chemically known as 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)- but more generally known as rabeprazole, which bears U.S. NIH Compound Identifier 5029. European Medicines Agency schedules Rabeprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10229MIG.

UNSPSC 51171983 Rabeprazole is a Commodity code that captures individual pharmaceutical products—in this case, a specific proton-pump inhibitor medication—that state and local health systems, correctional facilities, and pharmacy benefit programs procure through wholesale distribution channels and direct-to-manufacturer arrangements. Recent state and local solicitations show activity concentrated in correctional drug testing programs, multistate cooperative purchasing agreements for generic pharmaceuticals and OTC products, and emerging direct-to-manufacturer pharmacy initiatives that seek to bypass traditional pharmacy benefit managers and group purchasing organizations.

Activity under the code appears limited and geographically scattered. The most concrete recent opportunity is Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, estimated contract value $600,000), which does not directly procure rabeprazole but reflects how correctional systems source clinical and pharmaceutical services. More relevant is the Minnesota Multistate Cooperative Purchasing Alliance's (MMCAP) RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (responses due March 26, 2026), which established contracts effective July 1, 2026, for distribution across state and local government facilities in Minnesota and Oregon through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson. A third signal is the Texas Health and Human Services Commission's RFI HHS0017013 (April 3, 2026) exploring direct-to-manufacturer prescription programs to reduce intermediaries and improve cost management. State and local pharmaceutical procurement under this code moves through cooperative purchasing vehicles, correctional and health department budgets, and increasingly through direct-manufacturer relationships that reshape traditional wholesale channels.